How much does it cost to treat breast cancer for a whole year with Inavolisib?

Inavolisib is a highly selective inhibitor of PI3Kα and is mainly used to treat patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who carry PIK3CA gene mutations. It is often used in combination with palbociclib and fulvestrant to help control tumor growth and delay disease progression. As a targeted drug, the emergence of inaliset provides a new treatment option for breast cancer patients, especially for patients who are resistant to endocrine therapy.

In China, Inalise has just been approved for marketing, and the price per box is expected to be about 30,000 yuan. Usually, a box of medicine contains 7 tablets, and patients take one tablet every day. Approximately 4 boxes are needed every month to meet the treatment needs. Calculated based on this dose, the monthly drug cost is approximately 12 RMB. If treated for one year, the single drug cost will reach 144 RMB. Considering that Inalise has not yet been included in medical insurance, patients need to bear all costs out of their own pocket, which imposes a large financial burden on patients.

In addition, comprehensive treatment of breast cancer usually involves the cost of other drugs, such as palbociclib and fulvestrant, which are also expensive. Coupled with regular related examinations and follow-up monitoring, the overall treatment cost will further increase. During the treatment process, patients should communicate with their doctors in detail, and rationally plan medication and financial arrangements based on their own financial situation and treatment plan to ensure the smooth progress of treatment.

In general, inalise brings new hope for precise targeted treatment for patients with certain types of breast cancer, but because the price is high and it is not yet covered by medical insurance, patients need to be financially prepared. In the future, if there is medical insurance policy support or more generic drugs are launched, the burden on patients may be significantly reduced and more patients will benefit. Patients and family members should learn more about policies and market dynamics during the treatment process and strive to receive more help and support.

Reference materials:https://www.drugs.com/